Frequently Asked Questions
The market is segmented based on , By Technology {Diagnostics Methods, Screening Methods}, Screening Techniques (Carrier Screening, Sequential Screening, and Maternal Serum Quad Screening), Diseases (Alzheimer's Disease, Cancer, Cystic Fibrosis, Sickle Cell Anemia, Duchenne Muscular Dystrophy, Thalassemia, Huntington's Disease, Rare Diseases, Other Diseases), End User (Hospitals, Clinics, Diagnostic Centers), Product (Products, Consumables, Assay Kits, Reagents, Disposables, Instruments, Next Generation Sequencing Systems, Polymerase Chain Reaction Instruments, Microarrays, Ultrasound Devices, Other Instruments, Services) – Industry Trends and Forecast to 2030.
.
The Global Prenatal Genetic Testing Market size was valued at USD 9969.20 USD Billion in 2022.
The Global Prenatal Genetic Testing Market is projected to grow at a CAGR of 14.3% during the forecast period of 2023 to 2030.
The major players operating in the market include Abbott, Siemens Healthineers AG, Quidel Corporation, F. Hoffman-La Roche , Danaher, B.D., Chembio Diagnostics, Trinity Biotech plc, Instrumentation Laboratory, Nova Biomedical, PTS Diagnostics, Sekisui Diagnostics, Thermo Fisher Scientific, DiaSorin S.p.A, AccuBioTech Co. , Meridian Bioscience, GeneSTAT Molecular Diagnostics LLC, Terumo Corporation, Grifols S.A,.
The market report covers data from the U.S., Canada, and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.
